IN THE CLAIMS

Please amend Claims 1, 7, 17 and 18 and add new Claims 19 - 29 as follows:

a 18

1. (Amended) A compound of Formula (I):



(I)

wherein:

A is an aryl, heteroaryl, cycloalkyl, or heterocyclic group wherein said aryl, heteroaryl, cycloalkyl, or heterocyclic group is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, substituted amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, carboxyl, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, $-OS(O)_2$-alkyl, $-OS(O)_2$-substituted alkyl, $-OS(O)_2$-aryl, $-OS(O)_2$-substituted aryl, $-OS(O)_2$-heteroaryl, $-OS(O)_2$-substituted heteroaryl, $-OS(O)_2$-heterocyclic, $-OS(O)_2$-substituted heterocyclic, $-OSO_2$-NRR where each R is independently hydrogen or alkyl,$-NRS(O)_2$-NR-alkyl, $-NRS(O)_2$-NR-substituted alkyl, $-NRS(O)_2$-NR-aryl, $-NRS(O)_2$-

contd A18

NR-substituted aryl, -NRS(O)$_2$-NR-heteroaryl, -NRS(O)$_2$-NR-substituted heteroaryl, -NRS(O)$_2$-NR-heterocyclic, -NRS(O)$_2$-NR-substituted heterocyclic where R is hydrogen or alkyl,-N[S(O)$_2$-NR′]$_2$ where each R′ is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

HetAr is a nitrogen containing heteroaryl or a nitrogen containing substituted heteroaryl group;

Alk is an alkylene group of 1 to 4 carbons;

m is 0 or 1;

R^1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

X is selected from the group consisting of hydroxyl, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkenoxy, substituted cycloalkenoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy and -NR″R″ where each R″ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

and enantiomers, diastereomers and pharmaceutically acceptable salts thereof;

and further wherein the compound of Formula (I) has a binding affinity to VLA-4 as expressed by an IC$_{50}$ of about 15μM or less.

A19

7. (Amended) The compound of Claim 1 wherein HetAr is a nitrogen containing heteroaryl group is substituted with an aryl or substituted aryl group.

a 20

17. (Amended) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claims 1 - 9, 11, 12, 14 or 15.

18. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claims 1 - 9, 11, 12, 14 or 15.

a 21

19. (New) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 10.

20. (New) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 13.

21. (New) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of 14.

22. (New) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of 15.

contd.
a21

23. (New) A method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 16.

24. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 10.

25. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 13.

26. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 14.

27. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 15.

28. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 16.

29. (New) A compound selected from the group consisting of

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

contd. a 21

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(2-isopropyl)pyrimidin-4-yl)-L-3-(52-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

contd. a21

N-(2-(N,N-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

contd. a21

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(N,N-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(5-(2,5-dimethoxyphenyl)-pyridin-2-yl)alanine;

N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(5-(2-methoxyphenyl)-pyridin-2-yl)alanine;

N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(5-(N,N-dimethylamino-carbonyloxy)-pyridin-2-yl)alanine;

N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(2-(N,N-dimethylamino-carbonyloxy)-pyridin-5-yl)alanine; and

pharmaceutically acceptable salts thereof.